166 Results for "

RBD

" in MedChemExpress (MCE) Product Catalog:
Products (166)

166 Results for "RBD" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-15716
CAS No.: 436133-68-5
Purity:  99.93%
Target:  

Ras Apoptosis

Research Areas:  

Cancer

Kobe0065 is a novel and effective inhibitor of Ras-Raf interaction, competitively inhibiting the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki value of 46±13 μM.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P7436
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: 2019-nCov RBD Protein; 2019-nCoV Spike RBD Protein; S protein RBD; 2019-nCoV S protein RBD
Species:  
Source:  
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99435
CAS No.: 2509447-07-6
Synonyms: BRII-196

Target:  

SARS-CoV

Research Areas:  

Infection

Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P9801
Synonyms: SARS-CoV-2 (2019-nCoV) Spike RBD Antibody

Target:  

SARS-CoV

Research Areas:  

Infection

Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P78283
Purity:  ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: S protein RBD; S glycoprotein RBD; Spike protein RBD
Species:  
Source:  
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P73397
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: 2019-nCov RBD Protein; 2019-nCoV Spike RBD Protein; S protein RBD; 2019-nCoV S protein RBD
Species:  
Source:  
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-15717
CAS No.: 454453-49-7
Purity:  98.20%
Target:  

Ras

Research Areas:  

Cancer

Kobe2602 is a Ras-Raf interaction inhibitor. Kobe2602 inhibits the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki of 149 μM. Kobe2602 has antitumor activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N2116
CAS No.: 111047-30-4
Ginkgolic acid C17:1 is a fatty acid synthase (FAS) inhibitor with an IC50 of 10.5 µM. Ginkgolic acid C17:1 shows anti-tumor activity by inhibiting the phosphorylation of STAT3 and inducing apoptosis. Ginkgolic acid C17:1 can block the interaction between S-RBD and ACE2, and has anti-SARS-CoV-2-S pseudovirus activity. Ginkgolic acid C17:1 inhibits the biofilm formation of enterohemorrhagic Escherichia coli and Staphylococcus aureus .
loading...
    loading...
Cat. No.: HY-P99556
CAS No.: 2420564-02-7
Synonyms: AZD8895; COV2-2196

Target:  

SARS-CoV

Research Areas:  

Infection

Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor .
loading...
    loading...
Cat. No.: HY-126419
CAS No.: 124027-58-3
Purity:  99.90%
Kobophenol A, an oligomeric stilbene, blocks the interaction between the ACE2 receptor and S1-RBD with an IC50 of 1.81 μM and inhibits SARS-CoV-2 viral infection in cells with an EC50 of 71.6 μM. Kobophenol A inhibits the activity of partially purified rat brain protein kinase C (PKC) with an IC50 of 52 µM .
loading...
    loading...
Cat. No.: HY-144120
Target:  

SARS-CoV

Research Areas:  

Infection

αGalCer-RBD is a self-adjuvanting lipoprotein conjugate. αGalCer-RBD induces potent immunity against SARS-CoV-2 and its variants of concern. αGalCer-RBD conjugate induces RBD-specific, cytokine-producing T cell development. αGalCer-RBD has great potential to be an effective COVID-19 vaccine candidate. α-Galactosylceramide (αGalCer) is a potent invariant natural killer T cell (iNKT) agonist . RBD: receptor-binding domain
loading...
    loading...
Cat. No.: HY-149256
CAS No.: 1282451-83-5
Target:  

SARS-CoV

Research Areas:  

Infection

PLpro/RBD-IN-1 (compound 5) is a dual SARS-CoV-2 PLpro and spike protein RBD inhibitor with IC50s of 7.197 μM and 8.673 μM, respectively .
loading...
    loading...
Cat. No.: HY-P990814

Target:  

SARS-CoV

Research Areas:  

Infection

Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) reacts with the receptor binding domain (RBD) epitope B in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) can block the binding of the SARS-CoV-2 S protein to angiotensin-converting enzyme 2 (ACE2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) can be used for the research of SARS-CoV-2 infection .
loading...
    loading...
Cat. No.: HY-P990815

Target:  

SARS-CoV

Research Areas:  

Infection

Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) reacts with the receptor binding domain (RBD) epitope A in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) can block the binding of the SARS-CoV-2 S protein to angiotensin-converting enzyme 2 (ACE2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) can be used for the research of SARS-CoV-2 infection .
loading...
    loading...
Cat. No.: HY-P9802
Synonyms: SARS-CoV-2 (2019-nCoV) Single-Domain Antibodies; Humanized Single Domain Antibody

Target:  

SARS-CoV

Research Areas:  

Infection

Anti-Spike-RBD Single Domain mAb is a CHO cell derived Alpaca monoclonal VHH-huFc antibody, specifically binds to SARS-CoV-2 RBD with high affinity .
loading...
    loading...
Cat. No.: HY-P10803
Target:  

SARS-CoV

Research Areas:  

Infection

FLDKFNHEAEDLFYQSSL is an 18-residue peptide that binds to SARS-CoV-2 receptor-binding domain (RBD). FLDKFNHEAEDLFYQSSL inhibits the entry of SARS-Cov-2. FLDKFNHEAEDLFYQSSL also interacts with binding residues (Leu455, Phe456, Ala475 and Gln493) .
loading...
    loading...
Cat. No.: HY-P99104
CAS No.: 2529854-88-2
Synonyms: COVI-AMG; STI-2020

Target:  

SARS-CoV

Research Areas:  

Infection

Plutavimab a human IgG1-κ anti-SARS-CoV-2 antibody, targeting to Spike (S) glycoprotein receptor binding domain (RBD) .
loading...
    loading...
Cat. No.: HY-105086
CAS No.: 150332-35-7
Synonyms: CP148623
Target:  

SARS-CoV

Research Areas:  

Infection Metabolic Disease

Pamaqueside (CP148623) is a cholesterol absorption inhibitor and a potent binder of the SARS-CoV-2 receptor-binding domain (RBD), which may inhibit viral cellular entry. Pamaqueside can be utilized in metabolic and antiviral research .
loading...
    loading...
Cat. No.: HY-145644
CAS No.: 2599039-60-6
Synonyms: C-135-LS; BMS-986414

Target:  

SARS-CoV

Research Areas:  

Infection Cancer

Ogalvibart (C-135-LS) is a human anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model .
loading...
    loading...
Cat. No.: HY-145642
CAS No.: 2640223-84-1
Synonyms: ZRC3308-A7

Target:  

SARS-CoV

Research Areas:  

Infection

Masavibart (ZRC3308-A7) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Masavibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Masavibart can be used in combination with ZRC3308-B10 (HY-145643) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .
loading...
    loading...